💊 Pharmaceutical companies & CROs

Pharma and CROs use Legit.Health to automate clinical endpoints in dermatology trials: automatic severity scoring (PASI, SCORAD, IHS4, AUAS, SALT, GPPGA), image quality assurance (DIQA), and patient recruitment screening.

Direct customers (pharma)

Johnson & Johnson / Janssen

🇺🇸 US

Psoriasis Phase 3, Retrospective AD & Pso, Oncoderm RWE (Brazil)

Boehringer Ingelheim

🇩🇪 🇪🇸 DE / ES

GPPGA calculator, care provider sponsorship

Eli Lilly

🇭🇰 🇪🇸 HK / ES

SALT calculator, alopecia

Novartis

🇧🇷 BR

Hidradenitis suppurativa pilot

Pierre Fabre

🇫🇷 FR

Predictive SCORAD, Eczema Foundation

Sagimet Biosciences

🇺🇸 US

Alopecia Phase 3 (via ICON)

Almirall

🇪🇸 ES

HS studies, DCT consultancy

CRO partners

Indirect channel: CROs integrate Legit.Health into their clinical trial platforms. This multiplies our pharma reach without one-by-one BD.

Quantificare

🇫🇷 FR · Key partner

Sanofi AD trials (5 studies), Alopecia trial, Takeda AD

ICON (top-5 CRO globally)

🇺🇸 US · Active

Almirall HS trial, Protagonist Therapeutics Psoriasis Phase 2

PPD

🇺🇸 US · Pipeline

Symbio Research

🇺🇸 US · Pipeline

Fortrea

🇪🇺 EU · Pipeline

Eurofins Bioskin

🇩🇪 DE · Pipeline

Testimonial: Almirall

Diego Herrera (Almirall) and Taig Mac Carthy (Legit.Health) on digitalising clinical endpoints with AI.

The pain we solve

Pharmaceutical companies face the challenge of clinically validating treatments for skin disorders (psoriasis, atopic dermatitis, alopecia, hidradenitis suppurativa). Each clinical trial costs $49.3M on average (ASPE, 2014), takes ~4 years, and requires contracting CROs and expert consultants.

The pharma industry is moving toward Decentralised Clinical Trials (DCT) to recruit patients remotely, reduce costs, and speed up the process. However, DCTs require:

• Manual review by doctors to ensure patients fit inclusion criteria
• Manual severity assessment to measure treatment efficacy
• High image quality to avoid derailing the trial

How Legit.Health helps

1

Automatic recruitment

Diagnosis Support and Severity Assessment screen patients matching inclusion criteria.

2

Automated scoring

PASI, SCORAD, UAS, IHS4, SALT, GPPGA with reduced inter-rater variability.

3

Image quality (DIQA)

Proprietary algorithm filters non-diagnostic photos at scale.

The result: pharma saves cost, reduces risk, and accelerates clinical trials, while generating additional objective clinical endpoints automatically.